| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | AI | AJ | AK | AL | AM | AN | AO | AP | AQ | AR | AS | AT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Drug | INN | Date first registered by US FDA | Company or Companies | Indication | US FDA Orphan indications (23-10-2020) (designations) | Currency | Years since 1st US FDA approval | Cumulative revenue (in millions) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | ||
2 | Kyprolis | carfilzomib | 7/20/2012 | A general | Cancer: Multiple Myeloma | 1 | USD | 12.8 | $1,960 | $562 | $554 | $467 | $306 | $71 | $0 | ||||||||||||||||||||||||||||||||
3 | Humira | adalimumab | 12/31/2002 | Abbvie | Rheumatoid arthritis (initial indication, now many more) | 9 | USD | 22.1 | $228,328 | $14,404 | $21,237 | $20,694 | $19,832 | $19,169 | $19,936 | $18,427 | $16,078 | $14,012 | $12,543 | $10,659 | $9,265 | $7,932 | $6,508 | $5,500 | $4,500 | $3,000 | $2,000 | $1,500 | $852 | $280 | $0 | ||||||||||||||||
4 | Humira (US only) | adalimumab | 12/31/2002 | Abbvie | Rheumatoid arthritis (initial indication, now many more) | 9 | USD | 22.1 | $140,105 | $12,160 | $18,619 | $17,330 | $16,112 | $14,864 | $13,685 | $12,361 | $10,432 | $8,405 | $6,524 | $5,236 | $4,377 | ||||||||||||||||||||||||||
5 | Humira (USA Medicare part B) | adalimumab | 12/31/2002 | Abbvie | Rheumatoid arthritis (initial indication, now many more) | 9 | USD | 22.1 | $0 | ||||||||||||||||||||||||||||||||||||||
6 | Humira (USA Medicare part D) | adalimumab | 12/31/2002 | Abbvie | Rheumatoid arthritis (initial indication, now many more) | 9 | USD | 22.1 | $2,198 | ||||||||||||||||||||||||||||||||||||||
7 | Viekira | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | 12/19/2014 | Abbvie | HCV | 1 | USD | 10.5 | $178 | $784 | $1,522 | $1,639 | $48 | ||||||||||||||||||||||||||||||||||
8 | Viekira (US only) | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | 12/19/2014 | Abbvie | HCV | 1 | USD | 10.5 | $6 | $61 | $342 | $804 | $48 | ||||||||||||||||||||||||||||||||||
9 | Viekira (USA Medicare Part B) | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | 12/19/2014 | Abbvie | HCV | 1 | USD | 10.5 | $0 | ||||||||||||||||||||||||||||||||||||||
10 | Viekira (USA Medicare Part D) | dasabuvir sodium; ombitasvir; paritaprevir; ritonavir | 12/19/2014 | Abbvie | HCV | 1 | USD | 10.5 | $90 | $220 | |||||||||||||||||||||||||||||||||||||
11 | Ampyra | dalfampridine | 1/22/2010 | Acorda Therapeutics | MS | 2 | USD | 15.2 | $3,207 | $455 | $543 | $493 | $437 | $366 | $303 | $266 | $211 | $133 | |||||||||||||||||||||||||||||
12 | Ampyra (USA Medicare Part B) | dalfampridine | 1/22/2010 | Acorda Therapeutics | MS | 2 | USD | 15.2 | $0 | ||||||||||||||||||||||||||||||||||||||
13 | Ampyra (USA Medicare Part D) | dalfampridine | 1/22/2010 | Acorda Therapeutics | MS | 2 | USD | 15.2 | $206 | $176 | $136 | $99 | $72 | ||||||||||||||||||||||||||||||||||
14 | Soliris | eculizumab paroxysmal nocturnal hemoglobinuria | 3/16/2007 | Alexion | PNH; aHUS | 8 | USD | 18.0 | $28,981 | $1,874 | $4,064 | $3,946 | $3,563 | $3,144 | $2,843 | $2,591 | $2,234 | $1,551 | $1,134 | $783 | $541 | $387 | $259 | $66 | $0 | ||||||||||||||||||||||
15 | Soliris (US only) | eculizumab paroxysmal nocturnal hemoglobinuria | 3/16/2007 | Alexion | PNH; aHUS | 8 | USD | 18.0 | $7,305 | $1,588 | $1,235 | $1,059 | $944 | $730 | $561 | $400 | $263 | $206 | $160 | $113 | $46 | $0 | |||||||||||||||||||||||||
16 | Soliris (USA Medicare part B) | eculizumab paroxysmal nocturnal hemoglobinuria | 3/16/2007 | Alexion | PNH; aHUS | 8 | USD | 18.0 | $267 | $233 | $178 | $142 | $98 | ||||||||||||||||||||||||||||||||||
17 | Soliris (USA Medicare part D) | eculizumab paroxysmal nocturnal hemoglobinuria | 3/16/2007 | Alexion | PNH; aHUS | 8 | USD | 18.0 | $21 | $13 | $10 | $8 | $7 | ||||||||||||||||||||||||||||||||||
18 | Teflaro | ceftaroline fosamil for injection | 10/29/2010 | Allergan Sales (acquired Cerexa) | Acute skin infections, community-acquired pneumonia | 0 | USD | 14.5 | $577 | $128 | $122 | $134 | $138 | $56 | $0 | ||||||||||||||||||||||||||||||||
19 | Teflaro (USA Medicare Part B) | ceftaroline fosamil for injection | 10/29/2010 | Allergan Sales (acquired Cerexa) | Acute skin infections, community-acquired pneumonia | 0 | USD | 14.5 | $1 | $0.3 | $0.1 | $0.5 | $0.2 | ||||||||||||||||||||||||||||||||||
20 | Teflaro (USA Medicare Part D) | ceftaroline fosamil for injection | 10/29/2010 | Allergan Sales (acquired Cerexa) | Acute skin infections, community-acquired pneumonia | 0 | USD | 14.5 | $12 | $10 | $7 | $4 | $2 | ||||||||||||||||||||||||||||||||||
21 | Viibryd/Fetzima | vilazodone | 1/21/2011 | Allergan Sales (acquired Cerexa) | Mental illness: MDD | 0 | USD | 14.3 | $1,496 | $350 | $336 | $342 | $328 | $140 | $0 | ||||||||||||||||||||||||||||||||
22 | Viibryd/Fetzima (US only) | vilazodone | 1/21/2011 | Allergan Sales (acquired Cerexa) | Mental illness: MDD | 0 | USD | 14.3 | $342 | $333 | $342 | $328 | $140 | ||||||||||||||||||||||||||||||||||
23 | Viibryd/Fetzima (USA Medicare Part B) | vilazodone | 1/21/2011 | Allergan Sales (acquired Cerexa) | Mental illness: MDD | 0 | USD | 14.3 | $0 | $0 | $0 | $0 | $0 | ||||||||||||||||||||||||||||||||||
24 | Viibryd/Fetzima (USA Medicare Part D) | vilazodone | 1/21/2011 | Allergan Sales (acquired Cerexa) | Mental illness: MDD | 0 | USD | 14.3 | $74 | $66 | $57 | $42 | $22 | ||||||||||||||||||||||||||||||||||
25 | Vascepa | isocapent ethyl | 7/26/2012 | Amarin Pharms (Amarin parent based in Ireland) | hypertriglyceridemia | 0 | EUR | 12.8 | |||||||||||||||||||||||||||||||||||||||
26 | Enbrel | etanercept | 11/2/1998 | Amgen | Rheumatoid Arthritics; Plaque Psoriasis; Psoriaric Arthritics; Ankylosing Spondylitisl Juvenile Idiopathic Arthritis | 2 | USD | 26.2 | $26,464 | $5,014 | $5,433 | $5,965 | $5,364 | $4,688 | |||||||||||||||||||||||||||||||||
27 | Enbrel (US only) | etanercept | 11/2/1998 | Amgen | Rheumatoid Arthritics; Plaque Psoriasis; Psoriaric Arthritics; Ankylosing Spondylitisl Juvenile Idiopathic Arthritis | 2 | USD | 26.2 | $25,235 | $4,807 | $5,206 | $5,719 | $5,099 | $4,404 | |||||||||||||||||||||||||||||||||
28 | Enbrel (USA Medicare part B) | etanercept | 11/2/1998 | Amgen | Rheumatoid Arthritics; Plaque Psoriasis; Psoriaric Arthritics; Ankylosing Spondylitisl Juvenile Idiopathic Arthritis | 2 | USD | 26.2 | $0 | ||||||||||||||||||||||||||||||||||||||
29 | Enbrel (USA Medicare part D) | etanercept | 11/2/1998 | Amgen | Rheumatoid Arthritics; Plaque Psoriasis; Psoriaric Arthritics; Ankylosing Spondylitisl Juvenile Idiopathic Arthritis | 2 | USD | 26.2 | $1,572 | $1,385 | $1,198 | $977 | $722 | ||||||||||||||||||||||||||||||||||
30 | Prolia | denosumab | 6/1/2010 | Amgen | Osteoperosis | 2 | USD | 14.9 | $9,688 | $2,291 | $1,968 | $1,635 | $1,312 | $1,030 | $744 | $472 | $203 | $33 | $0 | ||||||||||||||||||||||||||||
31 | Prolia (US only) | denosumab | 6/1/2010 | Amgen | Osteoperosis | 2 | USD | 14.9 | $1,500 | $1,272 | $1,049 | $837 | |||||||||||||||||||||||||||||||||||
32 | Prolia (USA Medicare Part B) | denosumab | 6/1/2010 | Amgen | Osteoperosis | 2 | USD | 14.9 | $1,087 | $917 | $727 | $631 | $484 | ||||||||||||||||||||||||||||||||||
33 | Prolia (USA Medicare Part D) | denosumab | 6/1/2010 | Amgen | Osteoperosis | 2 | USD | 14.9 | $185 | $151 | $114 | $73 | $38 | ||||||||||||||||||||||||||||||||||
34 | Xgeva | denosumab | 6/1/2010 | Amgen | Osteoperosis | 2 | USD | 14.9 | $9,642 | $1,786 | $1,575 | $1,529 | $1,405 | $1,221 | $1,019 | $748 | $351 | $8 | $0 | ||||||||||||||||||||||||||||
35 | Xgeva (US only) | denosumab | 6/1/2010 | Amgen | Osteoperosis | 2 | USD | 14.9 | $1,338 | $1,157 | $1,115 | $1,006 | $857 | $764 | $644 | $343 | |||||||||||||||||||||||||||||||
36 | Xgeva (USA Medicare Part B) | denosumab | 6/1/2010 | Amgen | Osteoperosis | 2 | USD | 14.9 | $0 | $0 | $0 | $0 | $0 | ||||||||||||||||||||||||||||||||||
37 | Xgeva (USA Medicare Part D) | denosumab | 6/1/2010 | Amgen | Osteoperosis | 2 | USD | 14.9 | $15 | $12 | $9 | $6 | $4 | ||||||||||||||||||||||||||||||||||
38 | Edarbi | azilsartan kamedoxomil | 2/25/2011 | Arbor Pharmaceuticals LLC | HTN | EUR | 14.2 | ||||||||||||||||||||||||||||||||||||||||
39 | Horizant | gabapentin enacarbil | 4/6/2011 | Arbor Pharmaceuticals LLC | Restless Legs Syndrome | EUR | 14.1 | ||||||||||||||||||||||||||||||||||||||||
40 | Xtandi (Astellas fiscal year) | enzalutamide | 8/31/2012 | Astellas | Prostate cancer | 0 | JPY | 12.7 | ¥3,137,200 | ¥661,100 | ¥534,300 | ¥458,400 | ¥400,000 | ¥333,000 | ¥294,300 | ¥252,100 | ¥137,200 | ¥54,600 | ¥12,200 | ||||||||||||||||||||||||||||
41 | Xtandi, USA | enzalutamide | 8/31/2012 | Astellas | Prostate cancer | 0 | JPY | 12.7 | ¥1,024,100 | ¥276,900 | ¥238,600 | ¥203,500 | ¥164,700 | ¥140,400 | |||||||||||||||||||||||||||||||||
42 | Xtandi, Medicare (Federal fiscal year) | enzalutamide | 8/31/2012 | Astellas | Prostate cancer | 0 | USD | 12.7 | $12,687 | $2,437 | $2,411 | $1,969 | $1,421 | $1,183 | $855 | $908 | $790.66 | $447 | $232 | $35 | |||||||||||||||||||||||||||
43 | Xtandi, Medicaid (federal fiscal year) | $132 | $116 | $98 | $72 | $53 | |||||||||||||||||||||||||||||||||||||||||
44 | Xtandi (Pfizer/Medivation alliance revenue) | 8/31/2012 | Astellas | Prostate cancer | 0 | USD | 12.7 | $3,291 | $1,198 | $1,185 | $1,024 | $838 | $699 | $590 | $140 | ||||||||||||||||||||||||||||||||
45 | Brilinta | ticagrelor | 7/20/2011 | AstraZeneca | Acute coronary syndrome | 0 | USD | 13.8 | $4,727 | $1,321 | $1,079 | $839 | $619 | $476 | $283 | $89 | $21 | $0 | |||||||||||||||||||||||||||||
46 | Brilinta (US only) | ticagrelor | 7/20/2011 | AstraZeneca | Acute coronary syndrome | 0 | USD | 13.8 | $588 | $509 | $348 | $240 | $146 | $73 | $19 | $11 | |||||||||||||||||||||||||||||||
47 | Brilinta (USA Medicare Part B) | ticagrelor | 7/20/2011 | AstraZeneca | Acute coronary syndrome | 0 | USD | 13.8 | $0 | $0 | $0 | $0 | $0 | ||||||||||||||||||||||||||||||||||
48 | Brilinta (USA Medicare Part D) | ticagrelor | 7/20/2011 | AstraZeneca | Acute coronary syndrome | 0 | USD | 13.8 | $206 | $129 | $75 | $38 | $8 | ||||||||||||||||||||||||||||||||||
49 | Tagrisso | osimertinib | 11/13/2015 | AstraZeneca | Cancer: non-small-cell lung carcinomas | 2 | USD | 9.6 | $3,257 | $1,860 | $955 | $423 | $19 | $0 | |||||||||||||||||||||||||||||||||
50 | Tagrisso (US only) | osimertinib | 11/13/2015 | AstraZeneca | Cancer: non-small-cell lung carcinomas | 2 | USD | 9.6 | $869 | $405 | $255 | ||||||||||||||||||||||||||||||||||||
51 | Tagrisso (USA Medicare part B) | osimertinib | 11/13/2015 | AstraZeneca | Cancer: non-small-cell lung carcinomas | 2 | USD | 9.6 | $0 | ||||||||||||||||||||||||||||||||||||||
52 | Tagrisso (USA Medicare part D) | osimertinib | 11/13/2015 | AstraZeneca | Cancer: non-small-cell lung carcinomas | 2 | USD | 9.6 | $113 | ||||||||||||||||||||||||||||||||||||||
53 | Xiaflex | collagenase clostridium histolyticum | 2/2/2010 | Auxilium Pharmaceuticals (Acquired by Endo Pharmaceuticals) | Dupuytren's disease | 2 | USD | 15.2 | $826 | $265 | $213 | $190 | $158 | $0 | |||||||||||||||||||||||||||||||||
54 | Xiaflex (USA Medicare Part B) | collagenase clostridium histolyticum | 2/2/2010 | Auxilium Pharmaceuticals (Acquired by Endo Pharmaceuticals) | Dupuytren's disease | 2 | USD | 15.2 | $39 | $35 | $29 | $22 | $19.67 | ||||||||||||||||||||||||||||||||||
55 | Xiaflex (USA Medicare Part D) | collagenase clostridium histolyticum | 2/2/2010 | Auxilium Pharmaceuticals (Acquired by Endo Pharmaceuticals) | Dupuytren's disease | 2 | USD | 15.2 | $3 | $2 | $2 | $1 | $0.80 | ||||||||||||||||||||||||||||||||||
56 | Gadavist | gadobutrol | 3/14/2011 | Bayer Healthcare | CNS imaging | EUR | 14.1 | €2,174 | €366 | €365 | €346 | €290 | €233 | €205 | €209 | €160 | €0 | ||||||||||||||||||||||||||||||
57 | Gadavist (US only) | gadobutrol | 3/14/2011 | Bayer Healthcare | CNS imaging | EUR | 14.1 | €112 | €116 | €104 | €86 | ||||||||||||||||||||||||||||||||||||
58 | Gadavist (USA Medicare Part B) | gadobutrol | 3/14/2011 | Bayer Healthcare | CNS imaging | USD | 14.1 | $5 | $4 | $3 | $2 | $2 | |||||||||||||||||||||||||||||||||||
59 | Gadavist (USA Medicare Part D) | gadobutrol | 3/14/2011 | Bayer Healthcare | CNS imaging | USD | 14.1 | $0 | $0 | $0 | $0 | $0 | |||||||||||||||||||||||||||||||||||
60 | Natazia | estradial valerate/dienogest tabs | 5/6/2010 | Bayer Healthcare | Female birth control | EUR | 15.0 | ||||||||||||||||||||||||||||||||||||||||
61 | Nexavar | sorafenib | 12/1/2005 | Bayer Healthcare | Cancer: Hepatocellular carcinoma (HCC); renal cell carcinoma (RCC); thyroid carcinoma (DTC) | 5 | EUR | 19.3 | $8,540 | €712 | €834 | €870 | €892 | €773 | €771 | €792 | €725 | €705 | €604 | €462 | €270 | €130 | |||||||||||||||||||||||||
62 | Nexavar (US only) | sorafenib | 12/1/2005 | Bayer Healthcare | Cancer: Hepatocellular carcinoma (HCC); renal cell carcinoma (RCC); thyroid carcinoma (DTC) | 5 | EUR | 19.3 | $1,146 | €216 | €294 | €312 | €324 | ||||||||||||||||||||||||||||||||||
63 | Nexavar (USA Medicare part B) | sorafenib | 12/1/2005 | Bayer Healthcare | Cancer: Hepatocellular carcinoma (HCC); renal cell carcinoma (RCC); thyroid carcinoma (DTC) | 5 | USD | 19.3 | $0 | $0 | $0 | $0 | $0 | ||||||||||||||||||||||||||||||||||
64 | Nexavar (USA Medicare part D) | sorafenib | 12/1/2005 | Bayer Healthcare | Cancer: Hepatocellular carcinoma (HCC); renal cell carcinoma (RCC); thyroid carcinoma (DTC) | 5 | USD | 19.3 | $844 | $214 | $206 | $169 | $138 | $117 | |||||||||||||||||||||||||||||||||
65 | Stivarga | regorafenib | 9/27/2012 | Bayer Healthcare | Cancer: GIST | EUR | 12.6 | €315 | €315 | €275 | €313 | €224 | €197 | ||||||||||||||||||||||||||||||||||
66 | Stivarga (US only) | regorafenib | 9/27/2012 | Bayer Healthcare | Cancer: GIST | EUR | 12.6 | €149 | €166 | €142 | €181 | ||||||||||||||||||||||||||||||||||||
67 | Stivarga (USA Medicare Part B) | regorafenib | 9/27/2012 | Bayer Healthcare | Cancer: GIST | USD | 12.6 | $0 | $0 | $0 | $0 | $0 | |||||||||||||||||||||||||||||||||||
68 | Stivarga (USA Medicare Part D) | regorafenib | 9/27/2012 | Bayer Healthcare | Cancer: GIST | USD | 12.6 | $76 | $100 | $87 | $84 | $12 | |||||||||||||||||||||||||||||||||||
69 | Avonex | interferon beta-1a | 5/17/1996 | Biogen | MS | USD | 28.6 | $34,350 | $1,916 | $2,152 | $2,314 | $2,630 | $3,013 | $3,006 | $2,913 | $2,687 | $2,518 | $2,323 | $2,203 | $1,868 | $1,707 | $1,543 | $1,417 | $143 | |||||||||||||||||||||||
70 | Avonex (US only) | interferon beta-1a | 5/17/1996 | Biogen | MS | USD | 28.6 | $1,420 | $1,594 | $1,675 | $1,790 | $1,957 | $1,902 | $1,794 | |||||||||||||||||||||||||||||||||
71 | Avonex (USA Medicare Part B) | interferon beta-1a | 5/17/1996 | Biogen | MS | USD | 28.6 | $5 | $4 | $6 | |||||||||||||||||||||||||||||||||||||
72 | Avonex (USA Medicare Part D) | interferon beta-1a | 5/17/1996 | Biogen | MS | USD | 28.6 | $295 | $312 | $326 | $367 | $390 | |||||||||||||||||||||||||||||||||||
73 | Spinraza | nusinersen | 12/23/2016 | Biogen | Spinal muscular atrophy (SMA) | 1 | USD | 8.5 | $4,710 | $2,097 | $1,724 | $884 | $5 | ||||||||||||||||||||||||||||||||||
74 | Spinraza (US only) | nusinersen | 12/23/2016 | Biogen | Spinal muscular atrophy (SMA) | 1 | USD | 8.5 | $854 | $657 | $5 | ||||||||||||||||||||||||||||||||||||
75 | Spinraza (USA Medicare Part B) | nusinersen | 12/23/2016 | Biogen | Spinal muscular atrophy (SMA) | 1 | USD | 8.5 | $0 | ||||||||||||||||||||||||||||||||||||||
76 | Spinraza (USA Medicare Part D) | nusinersen | 12/23/2016 | Biogen | Spinal muscular atrophy (SMA) | 1 | USD | 8.5 | $0 | ||||||||||||||||||||||||||||||||||||||
77 | Tecfidera | dimethyl fumarate | 3/27/2013 | Biogen IDEC | MS | 0 | USD | 12.1 | $19,880 | $4,274 | $4,214 | $3,968 | $3,638 | $2,909 | $876 | ||||||||||||||||||||||||||||||||
78 | Tecfidera (US only) | dimethyl fumarate | 3/27/2013 | Biogen IDEC | MS | 0 | USD | 12.1 | $3,294 | $3,169 | $2,908 | $2,427 | $864 | ||||||||||||||||||||||||||||||||||
79 | Tecfidera (USA Medicare part B) | dimethyl fumarate | 3/27/2013 | Biogen IDEC | MS | 0 | USD | 12.1 | $0 | $0 | $0 | $0 | |||||||||||||||||||||||||||||||||||
80 | Tecfidera (USA Medicare part D) | dimethyl fumarate | 3/27/2013 | Biogen IDEC | MS | 0 | USD | 12.1 | $932 | $876 | $599 | $159 | |||||||||||||||||||||||||||||||||||
81 | Opdivo | nivolumab | 12/22/2014 | BMS | Cancer: NSCLC | 11 | USD | 10.5 | $23,609 | $7,204 | $6,735 | $4,948 | $3,774 | $942 | $6 | $0 | |||||||||||||||||||||||||||||||
82 | Opdivo (US only) | nivolumab | 12/22/2014 | BMS | Cancer: NSCLC | 11 | USD | 10.5 | $15,173 | $4,344 | $4,239 | $3,102 | $2,664 | $823 | $1 | ||||||||||||||||||||||||||||||||
83 | Opdivo (USA Medicare Part B) | nivolumab | 12/22/2014 | BMS | Cancer: NSCLC | 11 | USD | 10.5 | $0 | $0 | |||||||||||||||||||||||||||||||||||||
84 | Opdivo (USA Medicare Part D) | nivolumab | 12/22/2014 | BMS | Cancer: NSCLC | 11 | USD | 10.5 | $26 | $11 | |||||||||||||||||||||||||||||||||||||
85 | Pradaxa | dabigatran etexilate mesylate | 10/19/2010 | Boehringer Ingelheim | Stroke | 0 | EUR | 14.5 | €6,875 | 1,385 | 1,287 | 1,198 | 1,206 | 1,108 | $629 | $62 | $0 | ||||||||||||||||||||||||||||||
86 | Pradaxa (USA Medicare Part B) | dabigatran etexilate mesylate | 10/19/2010 | Boehringer Ingelheim | Stroke | 0 | USD | 14.5 | $0 | $0 | $0 | $0 | $0 | ||||||||||||||||||||||||||||||||||
87 | Pradaxa (USA Medicare Part D) | dabigatran etexilate mesylate | 10/19/2010 | Boehringer Ingelheim | Stroke | 0 | USD | 14.5 | $607 | $570 | $557 | $500 | $391 | ||||||||||||||||||||||||||||||||||
88 | Spiriva | Tiotropium Bromide | 1/30/2004 | Boehringer Ingelheim | COPD | 1 | EUR | 21.1 | €2,826 | €2,995 | €3,553 | €3,237 | €3,552 | €3,562 | €3,153 | ||||||||||||||||||||||||||||||||
89 | Spiriva (US only) | Tiotropium Bromide | 1/30/2004 | Boehringer Ingelheim | COPD | 1 | USD | 21.1 | $1,865 | ||||||||||||||||||||||||||||||||||||||
90 | Spiriva (USA Medicare Part B) | Tiotropium Bromide | 1/30/2004 | Boehringer Ingelheim | COPD | 1 | USD | 21.1 | $0 | $0 | $0 | $0 | $0 | ||||||||||||||||||||||||||||||||||
91 | Spiriva (USA Medicare Part D) | Tiotropium Bromide | 1/30/2004 | Boehringer Ingelheim | COPD | 1 | USD | 21.1 | $1,819 | $2,191 | $2,158 | $1,959 | $1,603 | ||||||||||||||||||||||||||||||||||
92 | Tradjenta | linagliptin | 5/2/2011 | Boehringer Ingelheim | Diabetes | 0 | EUR | 14.0 | €4,006 | 1,333 | 1,128 | $909 | $636 | $0 | |||||||||||||||||||||||||||||||||
93 | Tradjenta (USA Medicare part B) | linagliptin | 5/2/2011 | Boehringer Ingelheim | Diabetes | 0 | USD | $0 | |||||||||||||||||||||||||||||||||||||||
94 | Tradjenta (USA Medicare part D) | linagliptin | 5/2/2011 | Boehringer Ingelheim | Diabetes | 0 | USD | 14.0 | $708 | $508 | $292 | $153 | $35 | ||||||||||||||||||||||||||||||||||
95 | Daklinza | daclatasvir dihydrochloride | 7/24/2015 | Bristol-Myers Squibb (BMS) | HCV | USD | 9.9 | $386 | $1,550 | $1,315 | |||||||||||||||||||||||||||||||||||||
96 | Daklinza (USA Medicare Part B) | daclatasvir dihydrochloride | 7/24/2015 | Bristol-Myers Squibb (BMS) | HCV | USD | 9.9 | $0 | |||||||||||||||||||||||||||||||||||||||
97 | Daklinza (USA Medicare Part D) | daclatasvir dihydrochloride | 7/24/2015 | Bristol-Myers Squibb (BMS) | HCV | USD | 9.9 | $391 | $112 | ||||||||||||||||||||||||||||||||||||||
98 | Eliquis | apixaban | 12/28/2012 | Bristol-Myers Squibb (BMS) | Heart Disease: Stroke | 0 | USD | 12.4 | $7,929 | $6,438 | |||||||||||||||||||||||||||||||||||||
99 | Sprycel | dasatinib | 6/28/2006 | Bristol-Myers Squibb (BMS) | Cancer: Chronic Myeloid Leukemia (CML) | 4 | USD | 18.7 | $15,644 | $2,110 | $2,000 | $2,005 | $1,824 | $1,620 | $1,493 | $1,280 | $1,019 | $803 | $576 | $421 | $310 | $158 | $25 | $0 | |||||||||||||||||||||||
100 | Sprycel (US only) | dasatinib | 6/28/2006 | Bristol-Myers Squibb (BMS) | Cancer: Chronic Myeloid Leukemia (CML) | 4 | USD | 18.7 | $1,091 | $1,105 | $969 | $829 | $671 | $541 | $404 | $294 | $188 | $123 | $92 | $58 |